glp 1 novo GLP-1 RA education Novo Nordisk Forms GLP-1 Partnership
Description
Geriatric population increasingly require therapies that offer glycemic control, weight reduction benefits, and broader cardiometabolic support
Although the treatment landscape has expanded to include biologics and small-molecule agents, contemporary management is increasingly focused on altering the course of the disease rather than relying on symptom control alone
Saraceno N
What we do know is this: our sense of smell is not fixed
Highlight cardioprotective mechanisms of action of GLP-1 agonist
The primary outcome, AHI, showed a robust and statistically significant reduction with GLP-1 therapy (Fig
